Pluri Inc.
PLUR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001158780
In the last 90 days, Pluri Inc. insiders filed 1 open-market purchase and 0 sales; 16 institutions reported holding it in 13F filings for Q2 2026, worth $55.3K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:33 PM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2026: $23.8M (2344.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Revenue | $1.02M | $1.34M | $326.0K | $287.0K | $234.0K |
| Cost of revenue | $563.0K | $682.0K | $4.00K | $9.00K | – |
| Gross profit | $453.0K | $654.0K | $322.0K | $278.0K | – |
| Research and development | $15.1M | $12.9M | $12.4M | $17.4M | $24.6M |
| Selling, general and administrative | $10.3M | $9.98M | $10.0M | $11.8M | $17.4M |
| Operating income | -$24.9M | -$22.2M | -$22.2M | -$27.2M | -$41.6M |
| Interest expense | – | – | $866.0K | $843.0K | $887.0K |
| Income tax | -$25.0K | -$5.00K | – | – | – |
| Net income | -$23.8M | -$22.6M | -$20.9M | -$28.3M | -$41.2M |
| EPS, basic | $-2.44 | $-3.56 | $-3.99 | $-0.78 | $-1.28 |
| EPS, diluted | $-2.44 | $-3.56 | $-3.99 | $-0.78 | $-1.28 |
| Weighted shares, basic | 9.74M | 6.34M | 5.24M | 36.7M | 32.2M |
| Weighted shares, diluted | 9.74M | 6.34M | 5.24M | 36.7M | – |
| Margins and growth | |||||
| Gross margin | 44.6% | 49.0% | 98.8% | 96.9% | – |
| Operating margin | -2454.5% | -1659.9% | -6796.9% | -9493.4% | -17774.8% |
| Net margin | -2344.6% | -1690.3% | -6407.4% | -9867.9% | -17624.8% |
| Revenue growth, year over year | −24.0% | +309.8% | +13.6% | +22.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | $3.53M | $5.89M | $6.78M | $5.36M | $9.77M |
| Accounts receivable | – | – | – | – | $3.00K |
| Total current assets | $8.73M | $22.1M | $31.1M | $41.4M | $57.7M |
| Property, plant and equipment | $1.57M | $1.82M | $688.0K | $688.0K | $739.0K |
| Goodwill | $3.14M | $3.14M | – | – | – |
| Intangible assets | $2.61M | $2.79M | – | – | – |
| Total assets | $24.9M | $38.7M | $39.5M | $50.8M | $68.1M |
| Total current liabilities | $32.7M | $32.3M | $4.45M | $5.62M | $6.83M |
| Shareholders' equity | -$17.4M | -$865.0K | $5.42M | $15.3M | $32.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$19.6M | -$18.2M | -$18.0M | -$22.9M | -$36.5M |
| Capital expenditures | $633.0K | $1.62M | $323.0K | $262.0K | $280.0K |
| Free cash flow | -$20.2M | -$19.8M | -$18.3M | -$23.1M | -$36.8M |
| Depreciation and amortization | $511.0K | $316.0K | – | – | – |
| Stock-based compensation | $3.73M | $2.14M | $2.62M | $3.98M | $8.91M |
| Investing cash flow | $9.90M | $8.03M | $10.6M | $9.70M | $11.8M |
| Financing cash flow | $7.04M | $9.53M | $8.84M | $8.02M | $7.50M |
| Net change in cash | -$2.62M | -$475.0K | $1.42M | -$5.16M | -$20.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 366.7% | 160.4% | 803.1% | 1385.7% | 3807.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 9, 2026 | 12.3M | +51.4% | SEC |
| May 13, 2026 | 10.8M | +37.8% | SEC |
| Feb 11, 2026 | 10.1M | +43.6% | SEC |
| Nov 11, 2025 | 9.25M | +66.5% | SEC |
| Sep 16, 2025 | 8.16M | +49.1% | SEC |
| May 12, 2025 | 7.83M | +45.3% | SEC |
| Feb 10, 2025 | 7.00M | −83.1% | SEC |
| Nov 11, 2024 | 5.56M | −86.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Jun 30, 2021, from 13F share counts: 1-for-8 in Q2 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.